MétaCan
Menu
Back to cohort
Record W4327675561 · doi:10.1093/aje/kwad057

Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine

2023· article· en· W4327675561 on OpenAlexfundno aff
Michael Jetsupphasuk, Michael G. Hudgens, Haidong Lu, Stephen R. Cole, Jessie K. Edwards, Adaora A. Adimora, Keri N. Althoff, Michael J. Silverberg, Peter F. Rebeiro, Viviane D. Lima, Vincent C. Marconi, Timothy R. Sterling, Michael A. Horberg, M. John Gill, Mari M. Kitahata, Richard D. Moore, Raynell Lang, Kelly A. Gebo, Charles S. Rabkin, Joseph J. Eron

Bibliographic record

VenueAmerican Journal of Epidemiology · 2023
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsnot available
FundersEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institute on Minority Health and Health DisparitiesNational Institute of Child Health and Human DevelopmentNational Institute of Diabetes and Digestive and Kidney DiseasesNational Center for Research ResourcesNational Institute of Allergy and Infectious DiseasesNational Institute of Neurological Disorders and StrokeNational Institute of Nursing ResearchNational Institute of Mental HealthNational Heart, Lung, and Blood InstituteNational Institute on Alcohol Abuse and AlcoholismNational Eye InstituteNational Institute on AgingNational Cancer InstituteCanadian Institutes of Health ResearchNational Institutes of HealthGovernment of AlbertaAgency for Healthcare Research and QualityNational Center for Advancing Translational SciencesNational Human Genome Research InstituteHealth Resources and Services AdministrationNational Institute on Deafness and Other Communication DisordersNational Institute on Drug AbuseNational Institute of Dental and Craniofacial ResearchCenters for Disease Control and Prevention
KeywordsEfavirenzRegimenMedicineInternal medicineConfidence intervalCohortReverse-transcriptase inhibitorPediatricsViral loadHuman immunodeficiency virus (HIV)ImmunologyAntiretroviral therapy

Abstract

fetched live from OpenAlex

In first-line antiretroviral therapy (ART) for human immunodeficiency virus (HIV) treatment, some subgroups of patients may respond better to an efavirenz-based regimen than an integrase strand transfer inhibitor (InSTI)-based regimen, or vice versa, due to patient characteristics modifying treatment effects. Using data based on nearly 16,000 patients from the North American AIDS Cohort Collaboration on Research and Design from 2009-2016, statistical methods for precision medicine were employed to estimate an optimal treatment rule that minimizes the 5-year risk of the composite outcome of acquired immune deficiency syndrome (AIDS)-defining illnesses, serious non-AIDS events, and all-cause mortality. The treatment rules considered were functions that recommend either an efavirenz- or InSTI-based regimen conditional on baseline patient characteristics such as demographic information, laboratory results, and health history. The estimated 5-year risk under the estimated optimal treatment rule was 10.0% (95% confidence interval (CI): 8.6, 11.3), corresponding to an absolute risk reduction of 2.3% (95% CI: 0.9, 3.8) when compared with recommending an efavirenz-based regimen for all patients and 2.6% (95% CI: 1.0, 4.2) when compared with recommending an InSTI-based regimen for all. Tailoring ART to individual patient characteristics may reduce 5-year risk of the composite outcome compared with assigning all patients the same drug regimen.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.031
metaresearch head score (Gemma)0.069
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.031
Threshold uncertainty score0.163

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0310.069
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0020.001
Science and technology studies0.0000.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.173
GPT teacher head0.487
Teacher spread0.314 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueAmerican Journal of EpidemiologySame topicHIV/AIDS drug development and treatmentFrench-language works237,207